首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses.
【2h】

Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses.

机译:通过体内微透析对脑中他克林和单胺的测量反对由他克林以治疗剂量释放单胺。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The concentration of tacrine (tetrahydroaminoacridine or THA) in plasma, regions of brain and cerebral extracellular fluid has been studied in the rat at various times following injection of a dose of 5 mg kg-1, i.p. 2. The peak plasma THA concentration was 2.46 nmol ml-1, and occurred 30 min post injection and clearance was first order (t1/2 = 90 min). The concentration in the brain peaked between 30-60 min, and was around 30 times plasma concentration (striatum peak concentration = 65 +/- 3 nmol g-1). Extracellular cerebral concentration measured by in vivo microdialysis was similar to plasma concentration with the peak occurring 100 min post-injection. 3. No evidence was obtained by in vivo dialysis for THA inducing dopamine release from striatum or 5-hydroxytryptamine (5-HT) release from the frontal cortex. Enhanced release of dopamine did occur after (+)-amphetamine (5 mg kg-1, i.p.) injection, while KCl (100 mM) in the probe released both dopamine and 5-HT. 4. Since the minimum plasma THA concentration achieved in this study was at least twice that found in the plasma of patients given THA for the treatment of dementia, these results suggest that monoamine release in the brain does not occur during therapy.
机译:1.在注射5 mg kg-1(腹腔注射)剂量的大鼠后的不同时间,已研究了血浆,脑部和脑外液中他克林(四氢氨基ac啶或THA)的浓度。 2.血浆THA的峰值浓度为2.46 nmol ml-1,在注射后30分钟出现,清除率为一级(t1 / 2 = 90分钟)。脑中的浓度在30-60分钟之间达到峰值,约为血浆浓度的30倍(纹状体峰值浓度= 65 +/- 3 nmol g-1)。通过体内微透析测量的细胞外脑浓度类似于血浆浓度,其峰值出现在注射后100分钟。 3.体内透析未获得THA诱导纹状体释放多巴胺或额叶皮质释放5-羟色胺(5-HT)的证据。注射(+)-苯异丙胺(5 mg kg-1,i.p.)后,确实发生了多巴胺的增强释放,而探针中的KCl(100 mM)释放了​​多巴胺和5-HT。 4.由于该研究中获得的最低血浆THA浓度至少是接受THA治疗痴呆症患者血浆中血浆THA浓度的两倍,因此这些结果表明,在治疗期间脑中不会释放单胺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号